Lupus erythematosus tumidus

Summary

Lupus erythematosus tumidus (MONDO:0019560) is a disease and 5 clinical trials. Top therapeutic interventions include tetracaine. A subtype of chronic cutaneous lupus erythematosus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 12
• Clinical trials: 5

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		250	Worldwide	Validated

Signs & symptoms

Clinical features (HPO)

12 HPO clinical features (Orphanet curated; top 12 by frequency):

HPO ID	Term	Frequency
HP:0000992	Cutaneous photosensitivity	Very frequent (80-99%)
HP:0025474	Erythematous plaque	Very frequent (80-99%)
HP:0031191	Deep dermal perivascular inflammatory infiltrate	Very frequent (80-99%)
HP:0003493	Antinuclear antibody positivity	Occasional (5-29%)
HP:0025528	Annular cutaneous lesion	Occasional (5-29%)
HP:0030057	Autoimmune antibody positivity	Occasional (5-29%)
HP:0030351	Urticarial plaque	Occasional (5-29%)
HP:0032235	Anti-La/SS-B antibody positivity	Occasional (5-29%)
HP:0007483	Depigmentation/hyperpigmentation of skin	Excluded (0%)
HP:0040189	Scaling skin	Excluded (0%)
HP:0100699	Scarring	Excluded (0%)
HP:0020151	Anti-dsDNA antibody positivity	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	lupus erythematosus tumidus
Mondo ID	MONDO:0019560
Orphanet	90283
ICD-11	153320433
NCIT	C117112
SNOMED CT	200941006
UMLS	C0406636
MedGen	590566
GARD	0013003
Is cancer (heuristic)	no

Also known as: intermittent cutaneous lupus · LET · let · tumid lupus erythematosus

Disease family

This is a subtype of chronic cutaneous lupus erythematosus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › lupus erythematosus › cutaneous lupus erythematosus › chronic cutaneous lupus erythematosus › lupus erythematosus tumidus

Related subtypes (4): chilblain lupus, discoid lupus erythematosus, hypertrophic or verrucous lupus erythematosus, lupus erythematosus panniculitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04203225	PHASE4	COMPLETED	Comparison of Two Application Techniques for LET Gel
NCT04536493	PHASE4	COMPLETED	Comparison of 2 Application Techniques for LET Gel Used Prior to Simple Laceration Repair
NCT06868147	Not specified	RECRUITING	Long-term Clinical and Radiographic Results of Revision Anterior Cruciate Ligament Reconstruction Using a Single-bundle Technique and External Tenodesis With Achilles Tendon Allograft.
NCT06885372	Not specified	ENROLLING_BY_INVITATION	Long-term Follow up of the Stability 1 Trial
NCT07041242	Not specified	RECRUITING	Outcomes and Complication Rates of Anterior Cruciate Ligament Reconstruction Using the Over-the-top Technique Combined With Lateral Extra-articular Tenodesis in Patients Over 50 Years Old, Compared With a Control Group of Patients Under 30

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TETRACAINE	4	1